Lipopeptide delivery of siRNA to the central nervous system

Methods in Molecular Biology

Volumn 948, Issue , 2013, Pages 251-262

  Zabel, Mark D ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

Blood brain barrier; Central nervous system; Complexes; Delivery; Liposomes; Peptides; Prions; RNAi; siRNA

Indexed keywords

CHOLINERGIC RECEPTOR; LIPOPEPTIDE; LIPOSOME; NUCLEASE; PROTEINASE; SMALL INTERFERING RNA;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DEGRADATION; LIPOSOMAL GENE DELIVERY SYSTEM; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION;

EID: 84934443564     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-140-0_17     Document Type: Article

References (47)

1. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC (1998) Potent and speci fi c genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806-811
2. McCaffrey AP, Meuse L, Pham TT, Conklin DS, Hannon GJ, Kay MA (2002) RNA interference in adult mice. Nature 418:38-39
3. Paddison PJ, Caudy AA, Hannon GJ (2002) Stable suppression of gene expression by RNAi in mammalian cells. Proc Natl Acad Sci USA 99:1443-1448
4. Paddison PJ, Hannon GJ (2002) RNA interference: the new somatic cell genetics? Cancer Cell 2:17-23
5. Giladi H, Ketzinel-Gilad M, Rivkin L, Felig Y, Nussbaum O, Galun E (2003) Small interfering RNA inhibits hepatitis B virus replication in mice. Mol Ther 8:769-776
6. McCaffrey AP, Nakai H, Pandey K, Huang Z, Salazar FH, Xu H, Wieland SF, Marion PL, Kay MA (2003) Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol 21:639-644
7. Pai SI, Lin YY, Macaes B, Meneshian A, Hung CF, Wu TC (2006) Prospects of RNA interference therapy for cancer. Gene Ther 13:464-477
8. Campochiaro PA (2006) Potential applications for RNAi to probe pathogenesis and develop new treatments for ocular disorders. Gene Ther 13:559-562
9. Dorn G, Patel S, Wotherspoon G, Hemmings- Mieszczak M, Barclay J, Natt FJ, Martin P, Bevan S, Fox A, Ganju P, Wishart W, Hall J (2004) siRNA relieves chronic neuropathic pain. Nucleic Acids Res 32:e49
10. Kumar P, Wu H, McBride JL, Jung KE, Kim MH, Davidson BL, Lee SK, Shankar P, Manjunath N (2007) Transvascular delivery of small interfering RNA to the central nervous system. Nature 448:39-43
11. Pulford B, Reim N, Bell A, Veatch J, Forster G, Bender H, Meyerett C, Hafeman S, Michel B, Johnson T, Wyckoff AC, Miele G, Julius C, Kranich J, Schenkel A, Dow S, Zabel MD (2010) Liposome-siRNA-peptide complexes cross the blood-brain barrier and signi fi cantly decrease PrP on neuronal cells and PrP in infected cell cultures. PLoS One 5:e11085
12. Pfeifer A, Eigenbrod S, Al-Khadra S, Hofmann A, Mitteregger G, Moser M, Bertsch U, Kretzschmar H (2006) Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice. J Clin Invest 116:3204-3210
13. White MD, Farmer M, Mirabile I, Brandner S, Collinge J, Mallucci GR (2008) Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease. Proc Natl Acad Sci USA 105:10238-10243
14. D'Costa J, Mans fi eld SG, Humeau LM (2009) Lentiviral vectors in clinical trials: current status. Curr Opin Mol Ther 11:554-564
15. Dissen GA, Lomniczi A, Neff TL, Hobbs TR, Kohama SG, Kroenke CD, Galimi F, Ojeda SR (2009) In vivo manipulation of gene expression in non-human primates using lentiviral vectors as delivery vehicles. Methods 49:70-77
16. Lundberg C, Bjorklund T, Carlsson T, Jakobsson J, Hantraye P, Deglon N, Kirik D (2008) Applications of lentiviral vectors for biology and gene therapy of neurological disorders. Curr Gene Ther 8:461-473
17. Nanou A, Azzouz M (2009) Gene therapy for neurodegenerative diseases based on lentiviral vectors. Prog Brain Res 175:187-200
18. Mulligan RC (1993) The basic science of gene therapy. Science 260:926-932
19. Quinonez R, Sutton RE (2002) Lentiviral vectors for gene delivery into cells. DNA Cell Biol 21:937-951
20. Subramanya S, Kim S-S, Manjunath N, Shankar P (2010) RNA interference-based therapeutics for human immunode fi ciency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA? Expert Opin Biol Ther 10:201-213
21. Akhtar S, Benter IF (2007) Nonviral delivery of synthetic siRNAs in vivo. J Clin Invest 117:3623-3632
22. Mathupala SP (2009) Delivery of small-interfering RNA (siRNA) to the brain. Expert Opin Ther Pat 19:137-140
23. Meade BR, Dowdy SF (2008) Enhancing the cellular uptake of siRNA duplexes following noncovalent packaging with protein transduction domain peptides. Adv Drug Deliv Rev 60:530-536
24. Chiu YL, Ali A, Chu CY, Cao H, Rana TM (2004) Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem Biol 11:1165-1175
25. Muratovska A, Eccles MR (2004) Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett 558:63-68
26. Lafon M (2005) Rabies virus receptors. J Neurovirol 11:82-87
27. Lentz TL, Burrage TG, Smith AL, Crick J, Tignor GH (1982) Is the acetylcholine receptor a rabies virus receptor? Science 215:182-184
28. Barichello JM, Ishida T, Kiwada H (2010) Complexation of siRNA and pDNA with cationic liposomes: the important aspects in lipoplex preparation. Methods Mol Biol 605:461-472
29. Leng Q, Scaria P, Lu P, Woodle MC, Mixson AJ (2008) Systemic delivery of HK Raf-1 siRNA polyplexes inhibits MDA-MB-435 xenografts. Cancer Gene Ther 15:485-495
30. Leng Q, Woodle MC, Lu PY, Mixson AJ (2009) Advances in systemic siRNA Delivery. Drugs Future 34:721
31. Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W, Hartsough K, Machemer L, Radka S, Jadhav V, Vaish N, Zinnen S, Vargeese C, Bowman K, Shaffer CS, Jeffs LB, Judge A, MacLachlan I, Polisky B (2005) Potent and persistent in vivo anti-HBV activity of chemically modi fi ed siRNAs. Nat Biotechnol 23:1002-1007
32. Rothdiener M, Muller D, Castro PG, Scholz A, Schwemmlein M, Fey G, Heidenreich O, Kontermann RE (2010) Targeted delivery of siRNA to CD33-positive tumor cells with liposomal carrier systems. J Control Release 144:251-258
33. Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, Harborth J, Heyes JA, Jeffs LB, John M, Judge AD, Lam K, McClintock K, Nechev LV, Palmer LR, Racie T, Rohl I, Seiffert S, Shanmugam S, Sood V, Soutschek J, Toudjarska I, Wheat AJ, Yaworski E, Zedalis W, Koteliansky V, Manoharan M, Vornlocher HP, MacLachlan I (2006) RNAi-mediated gene silencing in nonhuman primates. Nature 441:111-114
34. Allen TM, Hansen C, Martin F, Redemann C, Yau-Young A (1991) Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta 1066:29-36
35. Harrington KJ, Rowlinson-Busza G, Syrigos KN, Uster PS, Abra RM, Stewart JS (2000) Biodistribution and pharmacokinetics of 111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model: implications for novel targeting strategies. Br J Cancer 83:232-238
36. Baru M, Carmel-Goren L, Barenholz Y, Dayan I, Ostropolets S, Slepoy I, Gvirtzer N, Fukson V, Spira J (2005) Factor VIII efficient and speci fi c non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic ef fi cacy. Thromb Haemost 93:1061-1068
37. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, Lee KD, Woodle MC, Lasic DD, Redemann C et al (1991) Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic ef fi cacy. Proc Natl Acad Sci USA 88:11460-11464
38. Harrington KJ, Rowlinson-Busza G, Uster PS, Stewart JS (2000) Pegylated liposome-encapsulated doxorubicin and cisplatin in the treatment of head and neck xenograft tumours. Cancer Chemother Pharmacol 46:10-18
39. Harrington KJ, Rowlinson-Busza G, Syrigos KN, Vile RG, Uster PS, Peters AM, Stewart JS (2000) Pegylated liposome-encapsulated doxorubicin and cisplatin enhance the effect of radiotherapy in a tumor xenograft model. Clin Cancer Res 6:4939-4949
40. Harrington KJ, Lewanski CR, Stewart JS (2000) Liposomes as vehicles for targeted therapy of cancer. Part 2: clinical development. Clin Oncol (R Coll Radiol) 12:16-24
41. Goebel FD, Goldstein D, Goos M, Jablonowski H, Stewart JS (1996) Ef fi cacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. The International SL-DOX Study Group. Br J Cancer 73:989-994
42. Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, Kaplan LD, Du Mond C, Mamelok RD, Henry DH (1998) Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 16:2445-2451
43. Zamboni WC, Ramalingam S, Friedland DM, Edwards RP, Stoller RG, Strychor S, Maruca L, Zamboni BA, Belani CP, Ramanathan RK (2009) Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies. Clin Cancer Res 15:1466-1472
44. Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, Roman L, Uziely B, Muderspach L, Garcia A, Burnett A, Greco FA, Morrow CP, Paradiso LJ, Liang LJ (1997) Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modi fi cation by liposomal encapsulation. J Clin Oncol 15:987-993
45. Ranson MR, Carmichael J, O'Byrne K, Stewart S, Smith D, Howell A (1997) Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 15: 3185-3191
46. Chekhonin VP, Zhirkov YA, Gurina OI, Ryabukhin IA, Lebedev SV, Kashparov IA, Dmitriyeva TB (2005) PEGylated immunoliposomes directed against brain astrocytes. Drug Deliv 12:1-6
47. Matveeva O, Nechipurenko Y, Rossi L, Moore B, Saetrom P, Ogurtsov AY, Atkins JF, Shabalina SA (2007) Comparison of approaches for rational siRNA design leading to a new efficient and transparent method. Nucleic Acids Res 35:e63